Details for Patent: 9,273,077
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 9,273,077 protect, and when does it expire?
Patent 9,273,077 protects ALUNBRIG and is included in one NDA.
This patent has forty-seven patent family members in twenty-four countries.
Summary for Patent: 9,273,077
Title: | Phosphorus derivatives as kinase inhibitors |
Abstract: | The invention features compounds of the general formula: ##STR00001## in which the variable groups are as defined herein, and to their preparation and use as protein kinase inhibitors. |
Inventor(s): | Wang; Yihan (Newton, MA), Huang; Wei-Sheng (Acton, MA), Liu; Shuangying (Wellesley, MA), Shakespeare; William C. (Southbourgh, MA), Thomas; R. Mathew (Sharon, MA), Qi; Jiwei (West Roxbury, MA), Li; Feng (Winchester, MA), Zhu; Xiaotian (Newton, MA), Kohlmann; Anna (Winchester, MA), Dalgarno; David C. (Brookline, MA), Romero; Jan Antoinette C. (Somerville, MA), Zou; Dong (Concord, MA) |
Assignee: | ARIAD Pharmaceuticals, Inc. (Cambridge, MA) |
Application Number: | 13/842,951 |
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 9,273,077
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Takeda Pharms Usa | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-001 | Apr 28, 2017 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) | See Plans and Pricing | ||||
Takeda Pharms Usa | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-002 | Apr 28, 2017 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) | See Plans and Pricing | ||||
Takeda Pharms Usa | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-003 | Oct 2, 2017 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | TREATMENT OF ANAPLASTIC LYMPHOMA KINASE (ALK)-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) | See Plans and Pricing | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,273,077
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2009248923 | See Plans and Pricing | |||
Brazil | PI0908637 | See Plans and Pricing | |||
Canada | 2723961 | See Plans and Pricing | |||
China | 102105150 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |